website translator

Bowtrol IBS Treatment Clinical Studies Bowtrol治疗肠易激综合征的临床研究

Probiotic Formula Eases Irritable Bowel syndrome Symptoms 益生菌公式例肠易激综合症的症状

DATE: April 2005 - DSIB 日期： 2005年4月- DSIB

NEW YORK-- Probiotic preparation containing Bowtrols Probiotic Lactospore relieved symptoms in patients suffering irritable bowel syndrome (IBS), according to a study published in the March issue of Gastroenterology. 纽约-益生菌准备载Bowtrols益生菌Lactospore缓解症状的患者肠易激综合征（ IBS ） ，根据研究成果发表在3月份的胃肠病。 In the study (128, 3:541-51), Irish researchers gave 77 IBS patients either B. infantis 35624, Lactobacillus salivarius UCC4331 (Lactospore) or placebo for eight weeks, and assessed various IBS symptoms daily. 在这项研究中（ 128 ， 3:541-51 ） ，爱尔兰的研究人员给77 IBS患者要么湾婴儿35624 ， UCC4331唾液乳杆菌（ Lactospore ）或安慰剂的8个星期，并评估各种日常肠易激综合征的症状。 B. infantis better alleviated all symptoms--including abdominal pain, bloating and bowel movement difficulty--than the other treatment. 湾婴儿更好地缓解症状-包括腹部疼痛，腹胀和大便困难-比其他治疗。 Researchers reported subjects' proinflammatory, Th-1 state was completely normalized by B. infantis feeding alone. 研究报告受试者炎症，钍- 1状态是完全正常的B.仅喂养婴儿。 They linked the effect to normalization of the ratio of an anti-inflammatory to a proinflammatory cytokine, suggesting an immune-modulating role for the probiotic strain in IBS patients. 他们联系在一起的效果正常化的比例消炎的促炎性细胞因子，提示免疫调节作用的益生菌株的IBS患者。 In addition, the scientists noted the symptom relief by B. infantis was comparable to effects shown by Zelnorm (tegaserod) and Lotronex (alosetron), two pharmaceuticals recently approved for IBS treatment. 此外，科学家们指出，症状救济的B.婴儿相比所表现出的影响服用Zelnorm （替加色罗）和Lotronex （阿洛司琼） ，两个最近批准的药品为治疗肠易激综合征。

Gastro-intestinal and associated effects ( L. Sporogenes ) 肠道和相关的影响 （属芽孢杆菌 ）

Reports from various hospitals that performed clinical trials on groups of patients suffering from a variety of intestinal disorders and allergic skin diseases are summarized in Table 5.1.It is evident that the administration of L. sporogenes markedly improved the general clinical condition of the subjects and provided relief from intestinal disorders and allergic skin conditions.报告从不同的医院进行临床试验组的患者的各种肠道疾病和过敏性皮肤疾病的摘要列于表5.1.It显而易见的是，行政属芽孢杆菌显着改善临床症状一般的主题，并提供减免肠道疾病和过敏性皮肤的条件。 Allergic skin conditions can be related to an imbalance of intestinal flora66 in the subject .过敏性皮肤条件可与不平衡flora66肠道中的问题。 This condition was therefore corrected by L. sporogenes therapy in these trials.这一条件，因此纠正由L.芽孢杆菌疗法在这些审判。

SUMMARY OF SELECTED CLINICAL REPORTS FROM JAPAN : TRIALS WITH LACBON ^Ò (L. Sporogenes)简要选定的临床报告来自日本：审判LACBON ^澳（湖芽孢杆菌）

1. 1 。 Condition: Acute and chronic intestinal catarrh 条件：急性和慢性肠卡

No. of subjects: 38 第主题： 38
Treatment: 100-600 million spores/ day in divided doses for 2-12 days 治疗： 100-600亿孢子/天剂量分为2-12天
Effectiveness rate: 86.8% 实效率： 86.8 ％
Conclusion: Recovery from diarrhea to regular normal stools; general symptoms including anorexia improved 结论：腹泻恢复正常正常大便;一般症状包括厌食改善

2. 2 。 Condition: Diarrhea 条件：腹泻

No. of subjects: 15 第主题： 15
Treatment: 75-600 million spores/ day in divided doses for 3-12 days 治疗： 75-600亿孢子/天剂量分为3-12天
Effectiveness rate: 100% 效力比例： 100 ％
Conclusion: Recovery from diarrhea to regular, normal stools from third to fourth day 结论：腹泻恢复正常，正常的大便从第三下降到了第4天

3. 3 。 Condition: Constipation 条件：便秘

No. of subjects: 10 第主题： 10
Treatment: 300-750 million spores / day in divided doses for 2-10 days 治疗： 300-750亿孢子/天剂量分为2-10天
Effectiveness rate: 70.0% 实效率： 70.0 ％
Conclusion: Recovery to normal stools and disappearance of abdominal distention 结论：恢复正常的粪便和失踪腹胀

4. 4 。 Condition: Abnormal intestinal fermentation 条件：肠道异常发酵

No. of subjects: 9 第主题： 9
Treatment: 300-600 million spores / day in divided doses for 3-14 days 治疗： 300-600亿孢子/天剂量分为3-14天
Effectiveness rate: 100.0% 实效率： 100.0 ％
Conclusion: Vomiting and nausea disappeared; appetite improved; stools became normal and regular; diarrhea and stomach ache cured. 结论：呕吐，恶心消失;食欲改善;大便正常和经常性;腹泻和胃痛治愈。

5. 5 。 Condition: Dyspepsia infantum 条件：婴儿消化不良

No. of subjects: 26 第主题： 26
Treatment: 100-200 million spores / day in divided doses for 1-7 days 治疗： 100-200亿孢子/天剂量分成1-7天
Effectiveness rate: 84.6% 实效率： 84.6 ％
Conclusion: General conditions and nature of stools improved. 结论：一般条件和性质的凳子改善。 Frequency of stools decreased to half or less than that before medication.大便的频率降低一半或少于前服药。

6. 6 。 Condition: Allergic skin diseases 条件：过敏性皮肤疾病

No. of subjects: 5 第主题： 5
Treatment: 200-450 million spores / day in divided doses for 4-12 days 治疗： 200-450亿孢子/天剂量分为4-12天
Effectiveness rate: 80.0% 实效率： 80.0 ％
Conclusion: Obvious eruptions of strophulus and eczema decreased from the third day (topical therapy employed concomitantly) 结论：明显的爆发strophulus和湿疹下降到第3天（局部治疗的同时雇用）

7. 7 。 Condition: Miscellaneous symptoms 条件：杂项症状

No. of subjects: 10 第主题： 10
Treatment: 20-50 million spores / day in divided doses for 4-20 days 治疗： 20-50亿孢子/天剂量分为4-20天
Effectiveness rate: 80.0% 实效率： 80.0 ％
Conclusion: Response seen in anorexia of nervous type and malnutrition in infants 结论：响应看到神经性厌食和营养不良型婴儿

The above data are cited from clinical reports by: Terumichi Kuniya, Pediatric Clinic of Shinko Hospital, Kobe; Jetsuo Nitta, Medical Clinic of Kugason Hospital; Goro Koide, Pediatric Clinic of Kanto Teishin Hospital; Michio Ogasawara, Medical Clinic of Kahoku Hospital; Susumu Nakazawa, Pediatric Clinic of Ebara Hospital.上述数据是引自临床报告：辉道Kuniya ，儿科诊所新光医院，神户; Jetsuo田，医疗诊所Kugason医院;戈罗小出，儿科门诊的关东Teishin医院;美智小笠原满男，医疗诊所河北医院;进中泽佑二，儿科诊所荏原医院。

Studies with SPORLAC ^Ò (L. sporogenes )59 in IndiaA total of 60 cases of neonatal diarrhea with watery stool frequency greater than 6 were examined for efficacy of SPORLAC treatment. 研究与SPORLAC ^澳（属芽孢杆菌） 59总数IndiaA在60例新生儿腹泻腹泻粪便频率大于6个检查效果SPORLAC治疗。 Based on the suggested dosage level of SPORLAC at 5 million spores per kilogram body weight, each neonate was given a spore level of about 15 million spores per day. Some of the subjects had associated symptoms in addition to diarrhea 根据建议的剂量水平SPORLAC 500万孢子每公斤体重，每一个新生儿得到了孢子水平的约1500万孢子每天。一些科目有相关症状除了腹泻

Most of the subjects (about 80%) had a history of breast-feeding.大多数受试者（约80 ％ ）的历史母乳喂养。 About 19% were both breast and bottle-fed and 1% were bottle-fed.The average duration for recovery was 1.8 days and the results of the study are tabulated:约19 ％都是乳房和奶瓶喂养和1 ％的人瓶fed.The平均时间为恢复为1.8天，研究结果统计：

As compared to the normal practice of administration of antibiotic and antidiarrheal mixtures, the complicating side effects were not seen in the series of SPORLAC trials.比较正常的行政管理实践中的抗生素和止泻的混合物，在复杂的副作用没有见过的一系列SPORLAC审判。 The average recovery time of 1.8 days helped to reduce dehydration in the subjects to a great extent.In a similar study in Japan(cited in 59) a comparable success rate of 78.4% with SPORLAC treatment for infantile diarrhea was obtained.平均恢复时间1.8天有助于减少脱水的主题伟大extent.In了一项类似的研究在日本（引自59岁）的可比成功率为78.4 ％与SPORLAC治疗婴幼儿腹泻获得。 An earlier study in India by Mathur et al.早先的研究在印度的马图等。 (cited in 59) found the average time for improvement in diarrheal conditions to be two to three days, with treatment. Other Clinical Trial References: （引自59岁）发现的平均时间为改善腹泻的条件是2至3天，与治疗。 其他临床试验参考文献：

Krivenko VV, Potebnia GP, Loiko VV ( 1989). Krivenko的VV ， Potebnia大奖赛， Loiko的VV （ 1989年） 。 Experience in treating digestive organ diseases with medicinal plants. 体会消化器官疾病的药用植物。 Vrach Delo. March(3):76-8 Vrach德乐。三月（ 3 ） :76 - 8

Achterrah-Tuckermann U., Kunde R., Flaskamp E., Isaac O., Thiemer K. (1980). Achterrah - Tuckermann美国， Kunde河， Flaskamp大肠杆菌，艾萨着， Thiemer光（ 1980年） 。 Pharmacological investigations with compounds of chamomile. 药理调查化合物甘菊。 5. Investigations on the spasmolytic effect of compounds of chamomile and kamillosan on the isolated guinea-pig ileum. 5 。案件的解痉作用的化合物，甘菊和kamillosan对豚鼠离体回肠。 Planta Medica 39(1):38-50 植物中药39 （ 1 ） :38 - 50

Mann, C. and EJ Staba. 曼恩， C.和膀胱Staba 。 1986. 1986年。 The Chemistry, Pharmacology, and Commercial Formulations of Chamomile. 化学，药理学和商业配方洋甘菊。 In LE Craker and JE Simon, eds. 在Le Craker西蒙和流行性乙型脑炎，合编。 Herbs, Spices, and Medicinal Plants: Recent Advances in Botany, Horticulture, and Pharmacology. 药草，香料，以及药用植物：最新进展植物学，园艺，和药理学。 Vol. 卷。 1. 1 。 Phoenix, AZ: Oryx Press. 凤凰城，亚利桑那州：羚羊出版社。 Pp. 235-280 页。 235-280

Mariann S., Gizella VP, Ede F. (1976). 玛丽安美国， Gizella副总裁埃德楼（ 1976年） 。 Antifungal effect of the biologically active components of Matricaria chamomilla L. Acta Pharm Hung. 抗真菌作用的生物活性成分的研究Matricaria chamomilla药学洪。 46(5-6):232- 47 46 （ 5-6 ） ： 232 - 47

Choi EM, Hwang JK (2004). 崔电磁，黄JK （ 2004 ） 。 Antiinflammatory, analgesic and antioxidant activities of the fruit of Foeniculum vulgare. 抗炎，镇痛及抗氧化活动的成果，小茴香。 Fitoterapia. 75(6):557-65. Fitoterapia 。 75 （ 6 ） :557 - 65 。

Yamahara, et. Yamahara等。 al. 基地。 1990. 1990年。 Gastrointestinal Motility Enhancing Effect of Ginger and its Active Constituents. 胃肠动力增强效应生姜及其活性成分。 Chem. 化学。 Pharm. 药学。 Bull. 红牛。 38(2):430-431. 38 （ 2 ） :430 - 431 。
Mustafa T., Srivastava KC, Jensen KB (1993) .Drug development report: 9. 穆斯塔法吨，斯塔瓦架KC ，延森kB的（ 1993年） 。药物发展报告： 9 。 Pharmacology of ginger, Zingiber officinale. 药理学生姜，生姜。 Journal of Drug Development 6(1) : 25-39 杂志药物开发6 （ 1 ） ： 25-39
Chevallier. Chevallier 。 A. The Encyclopedia of Medicinal Plants Dorling Kindersley. London 1996 ISBN 9-780751-303148 答：百科全书药用植物Dorling金德斯利。伦敦1996年书号9-780751-303148

Baschetti, R., New Zealand Medical Journal, April 26, 156-157, 1995 Baschetti ，河，新西兰医学杂志， 4月26日， 156-157 ， 1995

Grigoleit HG, Grigoleit P. (2005). Grigoleit汞， Grigoleit体育（ 2005 ） 。 Peppermint oil in irritable bowel syndrome. 薄荷油在肠易激综合症。 Phytomedicine12(8):601-6. Phytomedicine12 （ 8 ） :601 - 6 。